TIANJIN, China, July 20, 2021 / PRNewswire / – Juventas Cell Therapy Ltd., a Chinese biopharmaceutical company, has announced the closing of a more than $ 60 million Series C financing led by CICC Capital and Oceanpine Capital. Co-investors include Delian Capital and existing investors such as Jiadao Private Capital, Redhill Capital, Tianjin Venture Capital, Dalton Capital and RFUND. First, Juventas Cell Therapy Ltd. (hereinafter referred to as Juventas) plans to use the funds raised to advance the CD19 CAR-T CNCT19 candidate towards commercialization and development in the global market, second, with CAR technology, iPSCs technology and genes. Publishing technology platforms, autologous and universal / allogeneic / off-the-shelf products covering the treatment of hematologic tumors and solid tumors in the company’s pipeline will all be greatly fueled and propelled.
“We are grateful for the support of our existing and new investors. Juventas constantly appreciates and explores technological innovation in the field of cell and gene therapy. Guided by our development strategy of “rapid commercialization and internationalization”, we maintain deep cooperation with the first of world-class academic institutes and hospitals, build sustainable international research and development-innovation platforms for potential products and operate a pipeline competitive internationally while activating the corresponding clinical trials and commercialization process, “said Lv Lulu, Ph.D., CEO of Juventas,” for Juventas, the goal is to provide more patients with safe cell therapy products , efficient and accessible. “
“Immune cell therapy will be one of the dominant approaches for treating oncology in the future, although the development of new drugs and the commercialization of cell therapy products may be difficult, the application landscape is still unusually long. promising.”. Zhao Xinhao, CICC Capital Project Manager, presented: “Juventas has a core team that specializes in the entire industrial chain of R & D-production-sales in the field of cell therapy. By cooperating with from China leading research institutes and advancing candidates for commercialization and internationalization with the industrial mindset of innovative drugs, Juventas has become one of the leading companies in the Chinese cell immunotherapy sector. Its core product with independent intellectual property rights, CNCT19, originates from China. In Dec. 2020, CNCT19 has obtained the “Breakthrough Therapy Designation (BTD)” by the National Medical Products Administration (NMPA). CNCT 19 is expected to be the first CD19 CAR-T product with from China independent intellectual property rights that penetrate both Chinese and international markets. Meanwhile, one of the indications is acute lymphoblastic leukemia in adults, which so far has no CAR-T product marketed globally, is expected to receive New Drug Application (NDA) approval. and bring benefits to patients. CICC Capital is delighted to share sustainable industrial resources with Juventas and jointly drive the development of the cell immunotherapy business and industry. “
Mr. Chen Liguang, Managing Partner of Oceanpine Capital, points out that “demand growth in the biomedicine market is relentless. Naturally, innovation and internationalization will be the mainstream of from China new mechanism of drug development. Immune cell therapy drugs, as one of the representatives of Chinese innovative drugs, are of great value for long-term investment. We sincerely cherish and respect Juventas innovation in R&D and rapid commercialization capability. The partnership between us will meet the medical needs of the tumor market nationally and internationally. In addition, I believe that this cooperation will be a driving force in maintaining Juventas’ leadership position in the field of cell therapy. “
About Juventas Cell Therapy Ltd.
Founded in june 2018, Juventas Cell Therapy Ltd. is a next-generation biopharmaceutical company focused on innovative cell and gene technologies. Juventas has set up an innovative international R&D system for new drugs with CAR technology, iPSC technology and gene editing technology platform as the substrate and nucleus to develop the international competitive pipeline. Juventas form a deep cooperation with from China leading hospitals and clinical research institutes and is committed to building a preeminent platform for the R&D and commercialization of cell therapy products.
CNCT19, a CD19-targeted chimeric antigen receptor (CAR) T cell therapy, is Juventas’ first commodity, which is derived from the long-term innovative technology accumulation of the Institute of Hematology and of Blood Disease Hospital, Chinese Academy of Medicine Science. At Nov 29, 2019, the National Medical Products Administration (NMPA) has cleared its Investigational New Drug Application (IND) for CNCT19 from Juventas, and the corresponding indications are relapsed or refractory acute lymphoblastic B-cell leukemia (r / r B-ALL) and aggressive relapsed or refractory Non-Hodgkin’s B-cell lymphoma (r / r B-NHL). Currently, phase II clinical trials of CNCT19 (for ALL and NHL) are underway. In Dec. 2020, CNCT19 has obtained the “Breakthrough Therapy Designation (BTD)” by the National Medical Products Administration (NMPA). CNCT 19 is expected to be the first CD19 CAR-T product with from China independent intellectual property rights that penetrate both Chinese and international markets.
Juventas see the unmet clinical needs of patients as the guiding star. Through a strict cell therapy drug production and quality control system, every member of Juventas is committed to providing more patients with safe, effective and accessible cell therapy products. At the same time, Juventas systematically establishes an innovative and sustainable pipeline that covers hematological tumors, solid tumors and pioneering universal products. In addition, the company owns the world’s leading R&D technology platform, CMC platform, QC platform, and commercial production bases. As for Juventas’ production and R&D facilities in China, There is a 2000m2 R&D center at Beijing, and almost 10000m2 GMP production base in Tianjin.
SOURCE Juventas Cell Therapy Ltd.